# KCNN4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *KCNN4* gene encodes the intermediate-conductance calcium-activated potassium channel KCa3.1 (Gardos channel), crucial for calcium signaling, cell volume regulation, and immune cell activation across diverse cell types including erythrocytes, lymphocytes, and macrophages.
- Gain-of-function mutations in *KCNN4*, particularly at the Arg352 hotspot, cause dehydrated hereditary stomatocytosis (DHSt), a hemolytic anemia characterized by erythrocyte dehydration, with diagnosis aided by reticulocyte indices and flow cytometric osmotic fragility tests.
- KCa3.1 plays a critical role in T lymphocyte activation by maintaining the electrochemical gradient for sustained calcium influx, making it a therapeutic target for autoimmune diseases, and is also implicated in macrophage fusion and osteoclast formation.
- Dysregulation of KCa3.1 is implicated in cancer progression, promoting proliferation, migration, and angiogenesis, with its expression levels serving as prognostic biomarkers in pancreatic, lung, and thyroid cancers.
- KCa3.1 inhibitors, such as senicapoc, are being investigated for therapeutic applications in sickle cell disease, breast cancer, and renal fibrosis, while gene therapy approaches targeting KCNN4 are explored for epilepsy and cardiac cell therapy.
- *KCNN4* acts as a modifier gene in cystic fibrosis, influencing intestinal disease severity, and is associated with Crohn's disease and vascular disease susceptibility, highlighting its broader impact on complex pathologies.

---

## Executive Summary & Key Metadata

The *KCNN4* gene (Potassium Calcium-Activated Channel Subfamily N Member 4) encodes the intermediate-conductance calcium-activated potassium channel KCa3.1 (also known as IK1, SK4, or the Gardos channel). This channel is a critical mediator of calcium signaling in multiple cell types, including erythrocytes, lymphocytes, macrophages, epithelial cells, and various cancer cells. Its function spans cell volume regulation, immune cell activation, epithelial ion transport, and cancer cell proliferation and migration. Mutations in *KCNN4* cause a spectrum of hereditary hemolytic anemias, and its dysregulation is implicated in inflammatory diseases, fibrotic disorders, and multiple malignancies.

| **Metadata Field** | **Value** |
|---|---|
| **HGNC Symbol** | KCNN4 |
| **UniProt Accession** | O15554 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 19q13.2 |
| **Primary Molecular Function** | Calcium-activated potassium channel (intermediate conductance, KCa3.1); mediates K⁺ efflux following intracellular Ca²⁺ elevation |
| **Disease & Pathology Associations** | Dehydrated hereditary stomatocytosis (DHSt), Gardos channelopathy, cystic fibrosis modifier, inflammatory bowel disease (Crohn's disease), cancer (pancreatic, breast, lung, glioma, ovarian, thyroid, renal), vascular disease, asthma, renal fibrosis |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The *KCNN4* gene is located on the long arm of human chromosome 19 at band 19q13.2 [1]. This region is notable for being deleted in Diamond-Blackfan anemia, a rare congenital pure red cell aplasia, although *KCNN4* itself is not the causative gene for that disorder [1]. The gene spans approximately 40 kilobases of genomic DNA and consists of 11 exons, with the translation initiation codon located in exon 1 and the stop codon in exon 11.

The genomic architecture of *KCNN4* includes a complex promoter region with multiple transcription factor binding sites. The promoter lacks a canonical TATA box but contains GC-rich regions, consistent with a housekeeping-like expression pattern that is nonetheless subject to cell-type-specific regulation. The 5' flanking region contains binding sites for the repressor element-1 silencing transcription factor (REST), which has been demonstrated to regulate *KCNN4* expression in vascular smooth muscle cells [2, 3]. REST binding to the *KCNN4* promoter represses transcription, and downregulation of REST is a switch that enables *KCNN4* expression and subsequent cell proliferation [2].

### 1.2 Promoter Architecture and Epigenetic Regulation

The *KCNN4* promoter is subject to complex epigenetic regulation. In lung cancer, epigenetic dysregulation of *KCNN4* leads to altered expression levels that correlate with poor prognosis [4]. DNA methylation patterns in the promoter region and the first intron modulate gene expression, and histone acetylation status at the locus is dynamically regulated during cell activation.

A notable feature of the *KCNN4* gene is the presence of a guanine-rich minisatellite region capable of forming G-quadruplex (G4) structures. The first tandem repeat of this minisatellite folds into a V-loop G-quadruplex structure, which has been suggested to play a regulatory role in gene expression [5]. G4 structures in gene promoters typically modulate transcription by affecting the binding of transcription factors or RNA polymerase processivity.

### 1.3 Transcription Factor Binding and Enhancer Elements

Multiple transcription factors regulate *KCNN4* expression:

- **REST (RE1-Silencing Transcription Factor)**: Binds to a conserved RE1 element in the promoter and represses transcription in non-neuronal cells [2, 3]. REST downregulation in cancer cells leads to *KCNN4* upregulation.
- **Mineralocorticoid Receptor (MR)**: In the rat distal colon, multiple mineralocorticoid response elements (MREs) localized in different introns regulate *KCNN4* expression in response to aldosterone [6]. This regulation is critical for electrolyte transport in the colon.
- **Sp1 and Sp3**: GC-box binding factors that contribute to basal promoter activity.
- **NF-κB**: Inflammatory stimuli can induce *KCNN4* expression through NF-κB-dependent pathways, particularly in immune cells.

### 1.4 Alternative Splicing and Isoforms

The *KCNN4* gene undergoes alternative splicing that generates multiple transcript variants. The predominant transcript encodes the full-length KCa3.1 channel protein of 427 amino acids. Alternative splicing events include:

- **Exon 2 skipping**: Produces a truncated isoform lacking part of the N-terminal intracellular domain. This isoform may have altered channel gating properties.
- **Alternative 3' UTR usage**: Multiple polyadenylation sites produce transcripts with different 3' untranslated regions, which may affect mRNA stability and translational efficiency.
- **Alternative first exon usage**: Tissue-specific promoter usage generates transcripts with different 5' UTRs, potentially affecting translational regulation.

The functional significance of these isoforms remains incompletely characterized, but tissue-specific expression patterns suggest they may contribute to cell-type-specific channel properties.

### 1.5 Cross-Species Conservation

*KCNN4* is highly conserved across vertebrates. The mouse ortholog *Kcnn4* shares approximately 90% amino acid identity with the human protein. The rat ortholog has been extensively studied in the context of colonic ion transport [6] and salivary gland function [7, 8]. The high degree of conservation underscores the fundamental physiological importance of this channel.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

The KCa3.1 channel is a tetrameric protein complex, with each subunit containing six transmembrane domains (S1-S6). The channel belongs to the voltage-gated potassium channel superfamily but lacks a canonical voltage sensor, instead being gated primarily by intracellular calcium. Each subunit is 427 amino acids in length, with a molecular weight of approximately 48 kDa (glycosylated form ~55 kDa).

### 2.2 Domain Architecture (N-terminus to C-terminus)

**N-terminal Intracellular Domain (residues 1-90)**: This region contains the calmodulin-binding domain (CaMBD) that is essential for calcium-dependent gating. The N-terminus also contains a leucine zipper motif that may mediate protein-protein interactions. The extreme N-terminus (residues 1-30) is involved in channel tetramerization and contains determinants for trafficking to the plasma membrane.

**Transmembrane Domains (residues 91-330)**:
- **S1-S4 (residues 91-250)**: These four transmembrane segments form the "voltage sensor-like" domain. Although KCa3.1 is not voltage-gated in the classical sense, this domain contributes to the channel's gating properties and contains binding sites for several small-molecule modulators.
- **S5-S6 (residues 251-330)**: These segments form the pore domain. The S5-S6 linker contains the selectivity filter with the canonical potassium channel signature sequence (TVGYG), which confers K⁺ selectivity. The pore helix and selectivity filter are critical for ion conduction.

**C-terminal Intracellular Domain (residues 331-427)**: This region contains the second calmodulin-binding domain and is essential for calcium-dependent gating. The C-terminus also contains a PDZ-binding motif (ETDL at the extreme C-terminus) that mediates interactions with scaffolding proteins.

### 2.3 Calmodulin Binding and Calcium Sensing

The KCa3.1 channel is constitutively associated with calmodulin (CaM), which serves as the calcium sensor. Each channel subunit binds one CaM molecule. The CaMBDs in both the N- and C-termini contribute to CaM binding, with the C-terminal CaMBD being the primary high-affinity site. Upon calcium binding to CaM, a conformational change occurs that opens the channel pore.

The calcium sensitivity of KCa3.1 is remarkably high, with half-maximal activation at approximately 100-300 nM free intracellular calcium. This makes the channel exquisitely sensitive to physiological calcium signals. The calcium-calmodulin complex binds to the CaMBD with a stoichiometry of 1:1, and the gating mechanism involves a "calcium bridge" model in which CaM wraps around the CaMBD, pulling the channel into its open conformation.

### 2.4 Structural Studies and PDB Entries

Multiple high-resolution structures of KCa3.1 have been determined, primarily using cryo-electron microscopy (cryo-EM). Representative structures include:

- **PDB 6CNM**: Cryo-EM structure of the human KCa3.1 channel in complex with calmodulin in the calcium-bound (open) state.
- **PDB 6CNO**: Structure of the channel in the apo (closed) state.
- **PDB 6CNN**: Structure with the inhibitor TRAM-34 bound, revealing the drug-binding site in the central cavity.

These structures reveal that the channel forms a domain-swapped architecture typical of potassium channels, with the S1-S4 domain of one subunit interacting with the pore domain of the adjacent subunit. The calmodulin-binding domains form a "hanging gondola" structure beneath the transmembrane region, similar to that observed in other calcium-activated potassium channels.

### 2.5 Post-Translational Modifications

KCa3.1 is subject to multiple post-translational modifications that regulate its function:

- **N-glycosylation**: The channel is N-glycosylated at asparagine residues in the extracellular S3-S4 loop. Glycosylation is required for proper trafficking to the plasma membrane.
- **Phosphorylation**: Multiple phosphorylation sites exist, including sites for protein kinase C (PKC) and casein kinase 2 (CK2). Phosphorylation can modulate channel activity and surface expression.
- **Palmitoylation**: The channel is palmitoylated at cysteine residues in the C-terminal domain, which affects membrane localization and stability.
- **S-nitrosylation**: Nitric oxide can modify cysteine residues, potentially affecting channel function in vascular tissues.

### 2.6 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load KCNN4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15554)

The interactive visualizer allows exploration of the KCa3.1 channel structure, including the transmembrane domains, calmodulin-binding regions, and drug-binding sites. Users can rotate the structure, highlight specific domains, and examine the spatial relationships between functional elements.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biophysical Properties and Ion Conductance

KCa3.1 is an intermediate-conductance potassium channel with a single-channel conductance of approximately 20-40 pS in physiological potassium gradients. The channel is highly selective for K⁺ over Na⁺, with a selectivity ratio exceeding 100:1. The channel is activated by submicromolar concentrations of intracellular calcium and exhibits voltage-independent gating.

The primary function of KCa3.1 is to hyperpolarize the cell membrane in response to calcium signals. This hyperpolarization serves multiple purposes depending on cell type:

1. **Maintaining the electrical driving force for calcium entry**: In nonexcitable cells, membrane hyperpolarization increases the electrochemical gradient for Ca²⁺ entry through store-operated calcium channels (CRAC channels). This positive feedback loop amplifies calcium signals [1].
2. **Cell volume regulation**: K⁺ efflux through KCa3.1, accompanied by Cl⁻ efflux and osmotically obligated water, mediates regulatory volume decrease in response to cell swelling.
3. **Membrane potential stabilization**: In excitable cells, KCa3.1 contributes to the afterhyperpolarization that follows action potentials, regulating firing frequency [2, 3].

### 3.2 Role in Immune Cell Function

KCa3.1 is critically important for immune cell activation:

**T Lymphocytes**: Upon T cell receptor (TCR) engagement, intracellular calcium rises through CRAC channel activation. The resulting KCa3.1 activation hyperpolarizes the membrane, maintaining the driving force for sustained calcium entry [1]. This calcium signal is essential for NFAT nuclear translocation and cytokine gene expression. KCa3.1 blockade suppresses T cell proliferation and cytokine production, making it a therapeutic target for autoimmune diseases [4]. In T cells from immunodeficient patients with defective CRAC channel activation, KCa3.1 gating is also altered, demonstrating the functional coupling between these channels [1].

**B Lymphocytes**: KCa3.1 is expressed in B cells and is involved in B cell receptor-mediated calcium signaling. OCA-B (a B cell-specific coactivator) dependent genes include potassium channel genes, suggesting a link between transcriptional regulation and ion channel expression in B cell differentiation [5].

**Macrophages and Osteoclasts**: KCa3.1 regulates macrophage multinucleation and osteoclast formation [6]. A systems genetics approach in rat macrophages identified Kcnn4 as a determinant of macrophage fusion. KCa3.1 activity is required for the formation of multinucleated osteoclasts, and its inhibition reduces bone resorption [6, 7]. This has implications for inflammatory bone disease and osteoporosis.

**Mast Cells**: KCa3.1 is expressed in mast cells and contributes to their activation and degranulation. In the context of cystic fibrosis, Kcnn4 may modulate intestinal disease severity through effects on mast cell function [8].

**Microglia**: KCa3.1 is expressed in microglia and regulates their activation in neuroinflammatory conditions. The channel is implicated in Alzheimer's disease risk through microglial regulome analysis [1].

### 3.3 Role in Erythrocyte Function and the Gardos Pathway

In erythrocytes, KCa3.1 is known as the Gardos channel. It mediates calcium-activated potassium efflux, which is coupled to chloride efflux and water loss, leading to cell dehydration. This pathway is critical for:

- **Physiological volume regulation**: Erythrocytes use the Gardos pathway to regulate their volume in response to osmotic stress.
- **Sickle cell disease**: In sickle cell disease, the Gardos channel contributes to erythrocyte dehydration, which promotes hemoglobin S polymerization and sickling. KCa3.1 inhibitors have been explored as anti-sickling agents [2].
- **Hereditary stomatocytosis**: Gain-of-function mutations in KCNN4 cause dehydrated hereditary stomatocytosis (DHSt), characterized by erythrocyte dehydration and hemolytic anemia [3, 4, 5, 6].

### 3.4 Role in Epithelial Ion Transport

KCa3.1 is expressed in various epithelial tissues where it regulates ion transport:

**Salivary Glands**: KCa3.1 is the predominant calcium-activated potassium channel in parotid acinar cells [7, 8]. It provides the driving force for fluid and electrolyte secretion by maintaining a favorable electrical gradient for Cl⁻ efflux [7].

**Colon**: In the distal colon, KCa3.1 expression is regulated by aldosterone through mineralocorticoid response elements [6]. The channel provides the driving force for sodium absorption and potassium secretion.

**Airway Epithelium**: KCa3.1 is expressed in airway epithelial cells and regulates mucociliary clearance [8]. In muco-obstructive lung disease, lack of Kcnn4 improves mucociliary clearance, suggesting that channel inhibition may be therapeutic [8]. In chronic asthma models, KCa3.1 differentially regulates gene expression in trachea and bronchi [1].

**Pancreas**: KCa3.1 is present in both exocrine and endocrine pancreas [2]. In pancreatic acinar cells, it regulates fluid secretion. In pancreatic beta cells, it modulates insulin secretion by affecting membrane potential and calcium signaling.

### 3.5 Role in Cancer Biology

KCa3.1 is overexpressed in multiple cancer types and contributes to malignant phenotypes:

**Proliferation**: KCa3.1 activity promotes cell cycle progression in cancer cells. The channel is required for growth factor-induced proliferation in various cancer cell lines. REST downregulation in cancer cells enables KCNN4 expression and proliferation [2].

**Migration and Invasion**: KCa3.1 regulates cell migration by affecting cell volume changes and cytoskeletal dynamics. In glioblastoma, KCa3.1 is involved in migration, although acidic pH-induced migration may be independent of the channel [3].

**Angiogenesis**: KCa3.1 is expressed in endothelial cells and contributes to angiogenesis. The channel is involved in endothelial cell proliferation and tube formation.

**Tumor Microenvironment**: KCNN4 expression in cancer cells can remodel the tumor microenvironment. A pan-cancer study revealed that KCNN4 is associated with immune cell infiltration and may modulate the tumor immune response [4].

### 3.6 Mechanotransduction and Inflammasome Regulation

Recent work has revealed a novel role for KCNN4 in mechanotransduction and innate immunity. KCNN4 links PIEZO-dependent mechanotransduction to NLRP3 inflammasome activation [5]. In this pathway:

1. Mechanical stimuli activate PIEZO1 channels, leading to calcium influx.
2. The calcium signal activates KCa3.1, causing potassium efflux.
3. Reduced intracellular potassium triggers NLRP3 inflammasome assembly and IL-1β release.

This mechanism explains how environmental cues can trigger autoinflammatory responses in cryopyrin-associated periodic syndrome (CAPS) patients [5].

### 3.7 Protein-Protein Interaction Networks

KCa3.1 interacts with multiple proteins that regulate its function and localization:

| **Interaction Partner** | **Function** | **Reference** |
|---|---|---|
| Calmodulin (CaM) | Calcium sensing and channel gating | [3] |
| Protein disulfide isomerase (PDI) | Regulation of channel activity in endothelial cells | [6] |
| PIEZO1 | Mechanotransduction coupling | [5] |
| S100A14 | Prognostic marker interaction in ovarian cancer | [7] |
| REST | Transcriptional regulation | [2, 3] |
| GABRP | Regulation of calcium signaling in pancreatic cancer | [8] |

A comparative interactome analysis revealed architectural principles governing potassium channel function in cancer, highlighting that KCa3.1's interaction network differs across tumor types [1].

### 3.8 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["Extracellular Stimulus"] --> B["Receptor Activation"]
    B --> C["PLC Activation"]
    C --> D["IP3 Generation"]
    D --> E["ER Calcium Release"]
    E --> F["Intracellular Calcium Rise"]
    F --> G["CaM Binding to KCa3.1"]
    G --> H["Channel Opening"]
    H --> I["K+ Efflux"]
    I --> J["Membrane Hyperpolarization"]
    J --> K["Increased Ca2+ Influx via CRAC"]
    K --> F
    
    J --> L["Cell Volume Decrease"]
    L --> M["Regulatory Volume Decrease"]
    
    J --> N["Maintained Ca2+ Signal"]
    N --> O["NFAT Nuclear Translocation"]
    O --> P["Cytokine Gene Expression"]
    
    F --> Q["NLRP3 Inflammasome Activation"]
    Q --> R["IL-1beta Release"]
    
    H --> S["Proliferation/Migration"]
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Dehydrated Hereditary Stomatocytosis (DHSt)

Mutations in KCNN4 are a major cause of dehydrated hereditary stomatocytosis (DHSt), also known as hereditary xerocytosis [3, 5, 6]. DHSt is an autosomal dominant hemolytic anemia characterized by erythrocyte dehydration, stomatocyte morphology, and compensated hemolysis.

**Key Mutations in KCNN4-Associated DHSt:**

| **Mutation** | **Protein Change** | **Phenotype** | **Reference** |
|---|---|---|---|
| c.1055G>A | p.Arg352His | Classic DHSt with hemolytic anemia | [3, 6] |
| c.1054C>T | p.Arg352Cys | DHSt with variable severity | [5] |
| c.1181G>A | p.Arg394His | DHSt with hemolytic anemia | [4] |
| c.1216A>G | p.Lys406Glu | DHSt with atypical features | [4] |
| c.665T>C | p.Val222Leu | DHSt with stomatocytosis without erythrocyte dehydration | [2] |
| c.1018C>A | p.His340Asn | DHSt with stomatocytosis without erythrocyte dehydration | [2] |

The Arg352 residue is a mutational hotspot, with both Arg352His and Arg352Cys mutations reported. These mutations are located in the calmodulin-binding domain and produce gain-of-function effects by increasing calcium sensitivity or altering channel gating kinetics [3, 6].

### 4.2 Gardos Channelopathy

The term "Gardos channelopathy" encompasses a broader spectrum of KCNN4 mutations associated with hereditary stomatocytosis [3, 4]. Novel insights into KCNN4 mutations and their clinical impact have revealed:

- **Variable expressivity**: Even within the same family, affected individuals can show significant variation in anemia severity [5, 6].
- **Complex molecular regulation**: Some mutations affect not only channel gating but also channel trafficking and surface expression [4].
- **Fetal complications**: Severe KCNN4 mutations can cause nonimmune hydrops fetalis and fetal loss [7].

### 4.3 Mutations Without Erythrocyte Dehydration

A distinct class of KCNN4 mutations (e.g., V222L and H340N) causes stomatocytosis without erythrocyte dehydration [2]. These mutations are located outside the calmodulin-binding domain and may affect channel properties differently than the classic DHSt mutations. This suggests that the genotype-phenotype correlation in KCNN4-associated disorders is more complex than initially appreciated.

### 4.4 Clinical Differential Diagnosis

The differential diagnosis of KCNN4-associated DHSt includes:

- **PIEZO1-associated DHSt**: PIEZO1 mutations are the most common cause of DHSt [1, 8]. PIEZO1-associated DHSt tends to have more severe clinical features, including perinatal edema and more pronounced hemolysis.
- **Other hereditary stomatocytoses**: Overhydrated hereditary stomatocytosis (due to RhAG mutations) and other rare forms.
- **Autoimmune hemolytic anemia**: Can present with similar laboratory findings but has a different clinical context.
- **Sickle cell disease**: Shares erythrocyte dehydration features but has distinct pathophysiology.

### 4.5 Diagnostic Approaches

Diagnosis of KCNN4-associated DHSt requires:

1. **Clinical evaluation**: History of hemolytic anemia, splenomegaly, gallstones.
2. **Laboratory findings**: Elevated MCHC, decreased osmotic fragility, reticulocytosis.
3. **Reticulocyte indices**: Rapid diagnosis can be achieved using reticulocyte indices [2].
4. **Flow cytometric osmotic fragility test**: An effective screening method for DHSt [3].
5. **Genetic testing**: Sanger sequencing or targeted next-generation sequencing of KCNN4 and PIEZO1.

### 4.6 KCNN4 as a Modifier Gene

Beyond its role as a primary disease gene, KCNN4 acts as a modifier gene in other conditions:

**Cystic Fibrosis**: KCNN4 is a modifier gene of intestinal cystic fibrosis severity [4, 8]. In the Cftr-F508del mouse model, Kcnn4 deficiency prevents lethality from intestinal obstruction [4]. In humans, polymorphic markers in KCNN4 are associated with meconium ileus in cystic fibrosis neonates [5]. This modifier effect may be mediated through mast cell function [8].

**Crohn's Disease**: A KCNN4 gene variant is associated with ileal Crohn's disease in Australian and New Zealand populations [6, 7]. This association suggests that KCa3.1 function influences inflammatory bowel disease susceptibility.

**Vascular Disease**: Haplotypes of the KCNN4 gene are associated with susceptibility to human vascular diseases in Japanese populations [8].

### 4.7 Cancer-Associated KCNN4 Alterations

While KCNN4 is not typically mutated in cancer, its expression is frequently dysregulated:

- **Pancreatic adenocarcinoma**: KCNN4 expression has prognostic value [1]. GABRP regulates pancreatic cancer progression through tuning KCNN4-mediated calcium signaling [8].
- **Lower grade glioma**: Increased KCNN4 expression correlates with poor survival [2].
- **Non-small cell lung cancer**: KCNN4 is a novel therapeutic target [3].
- **Papillary thyroid cancer**: KCNN4 is a diagnostic and prognostic biomarker [4].
- **Renal clear cell carcinoma**: KCNN4-related ceRNA network and prognostic model have been developed [5].
- **Ovarian cancer**: KCNN4 and S100A14 predict recurrence in serous ovarian cancer [7]. Pharmacologic activation of KCNN4 increases sensitivity to cisplatin [6].
- **Breast cancer**: KCNN4 is a druggable target identified by Mendelian randomization [7, 8]. Senicapoc, a KCNN4 inhibitor, shows potential for prevention and treatment [1].

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions

KCNN4 expression can be modulated by viral infections, and the channel may play roles in viral pathogenesis:

**Influenza Virus**: In MDCK cells used for vaccine production, RSAD2 (viperin) is an effective target for high-yield vaccine production [2]. While KCNN4 is not directly implicated, the broader ion channel expression changes during viral infection may affect viral replication.

**Radiation Response**: KCNN4 shows discordant gene responses to radiation in humans and mice [3, 4]. This discordance is important for developing radiation biomarkers and understanding species-specific responses to genotoxic stress.

### 5.2 Bacterial Interactions

**Periodontitis**: Exosome-related lactylation gene signatures, which may include KCNN4, define diagnostic biomarkers of periodontitis [5]. This suggests that KCNN4 is involved in the host response to oral bacterial pathogens.

### 5.3 Immune Evasion Mechanisms

KCNN4's role in immune cell function makes it a potential target for immune evasion:

- **Tumor immune evasion**: KCNN4 expression in cancer cells can remodel the tumor microenvironment, potentially promoting immune evasion [4]. The channel affects immune cell infiltration and function within tumors.
- **Inflammasome regulation**: KCNN4-mediated potassium efflux is required for NLRP3 inflammasome activation [5]. Pathogens that modulate KCNN4 activity could potentially suppress inflammasome responses.

### 5.4 Cytosolic Delivery and Pathogen-Derived Peptides

KCNN4 is a genomic determinant of cytosolic delivery by the attenuated cationic lytic peptide L17E [6]. This finding has implications for drug delivery and potentially for understanding how certain peptides (including antimicrobial peptides) interact with host cells. The KCNN4-dependent pathway for peptide internalization may be exploited by pathogens or therapeutic peptides.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 KCa3.1 as a Drug Target

KCa3.1 is an attractive therapeutic target due to its involvement in multiple disease processes [7, 8]. The channel's restricted expression pattern and defined physiological roles make it amenable to pharmacological intervention.

### 6.2 Small-Molecule Inhibitors

**TRAM-34**: A triarylmethane compound that is the prototypical KCa3.1 inhibitor. TRAM-34 binds in the central cavity of the channel pore and blocks potassium conductance. It has been extensively used in preclinical studies.

**Senicapoc (ICA-17043)**: A potent and selective KCa3.1 inhibitor that has advanced to clinical trials. Senicapoc was originally developed for sickle cell disease but has shown promise in other indications:

- **Sickle cell disease**: Senicapoc reduces erythrocyte dehydration and sickling [2].
- **Breast cancer**: Senicapoc shows potential for prevention and treatment of breast cancer [1].
- **Renal fibrosis**: Senicapoc reduces renal inflammation and fibrosis in mouse models [1].

**Clotrimazole**: An antifungal agent that inhibits KCa3.1, though with less selectivity than TRAM-34 or senicapoc.

**Other Investigational Compounds**: Multiple novel KCa3.1-targeting small molecules are in development [2]. These include compounds with improved selectivity and pharmacokinetic properties.

### 6.3 Monoclonal Antibodies

Monoclonal antibodies targeting KCa3.1 are being developed [2]. These antibodies can provide greater specificity than small molecules and may have utility in imaging or targeted drug delivery.

### 6.4 Gene Therapy Approaches

**Epilepsy**: Overexpression of KCNN4 channels in principal neurons produces an anti-seizure effect without reducing their coding ability [3]. This suggests that KCNN4 gene therapy could be a treatment for epilepsy. However, overexpression can also deteriorate channel functionality and availability at the outer cellular membrane [4], highlighting the need for careful dose optimization.

**Cardiac Applications**: Electrophysiological engineering of heart-derived cells with calcium-dependent potassium channels improves cell therapy efficacy for cardioprotection [5]. KCNN4 expression in cardiac progenitor cells may enhance their therapeutic potential.

### 6.5 Pharmacogenomic Considerations

**Drug Response Variability**: KCNN4 polymorphisms may affect individual responses to KCa3.1-targeting drugs. The association of KCNN4 haplotypes with vascular disease susceptibility [8] suggests that genetic variation in KCNN4 could influence drug efficacy.

**Drug Repurposing**: Mendelian randomization studies have identified KCNN4 as an actionable druggable target for breast cancer [7, 8]. This approach supports drug repurposing of KCa3.1 inhibitors for cancer prevention and treatment.

### 6.6 Therapeutic Applications by Disease

| **Disease** | **Therapeutic Approach** | **Stage** | **Reference** |
|---|---|---|---|
| Sickle cell disease | Senicapoc (KCa3.1 inhibitor) | Clinical trials | [2] |
| Breast cancer | Senicapoc | Preclinical | [1] |
| Renal fibrosis | Senicapoc | Preclinical | [1] |
| Epilepsy | KCNN4 gene therapy | Preclinical | [3] |
| Multiple sclerosis | KCa3.1 blockade | Preclinical | [4] |
| Glioma | KCa3.1 targeting | Preclinical | [6] |
| Asthma | KCa3.1 modulation | Preclinical | [1] |
| Cystic fibrosis | KCa3.1 inhibition | Preclinical | [4, 8] |
| Inflammatory bowel disease | KCa3.1 modulation | Preclinical | [6, 7] |

## 7. Bioinformatic Resources & Database Accessions

### 7.1 Key Database Entries

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 3783 | Gene entry for KCNN4 |
| Ensembl | ENSG00000104783 | Gene annotation |
| UniProt | O15554 | Protein sequence and annotation |
| RCSB PDB | 6CNM, 6CNO, 6CNN | 3D structures |
| HGNC | 6292 | Gene nomenclature |
| OMIM | 602754 | Mendelian inheritance |
| ClinVar | Various | Clinical variants |
| STRING | 9606.ENSP00000262255 | Protein-protein interactions |
| BioGRID | 121422 | Interaction data |
| Gene Ontology | GO:0015269, GO:0005516, GO:0006813 | Calcium-activated potassium channel activity, calmodulin binding, potassium ion transport |
| Reactome | R-HSA-1296052 | Calcium-activated potassium channels |
| KEGG | hsa:3783 | Pathway annotations |

### 7.2 Gene Ontology Terms

**Molecular Function:**
- GO:0015269: Calcium-activated potassium channel activity
- GO:0005516: Calmodulin binding
- GO:0005267: Potassium channel activity
- GO:0046873: Metal ion transmembrane transporter activity

**Biological Process:**
- GO:0006813: Potassium ion transport
- GO:0006811: Ion transport
- GO:0007268: Chemical synaptic transmission
- GO:0006954: Inflammatory response
- GO:0008283: Cell population proliferation
- GO:0019722: Calcium-mediated signaling

**Cellular Component:**
- GO:0016021: Integral component of membrane
- GO:0005886: Plasma membrane
- GO:0008076: Voltage-gated potassium channel complex
- GO:0043235: Receptor complex

### 7.3 Expression Databases

- **GTEx**: KCNN4 is expressed in multiple tissues, with highest expression in the gastrointestinal tract, spleen, and lung.
- **Human Protein Atlas**: Protein expression data across tissues and cancer types.
- **CCLE**: Cancer cell line expression data.

### 7.4 Clinical Resources

- **ClinVar**: Contains pathogenic variants associated with DHSt and Gardos channelopathy.
- **gnomAD**: Population frequency data for KCNN4 variants.
- **DECIPHER**: Genotype-phenotype correlations.

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Islam S, Tushar MH, Sarkar B, Moni R, Zohora US, Rahman MS. Investigating the prognostic value of KCNN4 gene expression in human pancreatic adenocarcinoma by bioinformatic analysis. bioRxiv. 2025. URL: https://www.semanticscholar.org/paper/d7ddb53c721c1234975329443b4c893f7df08882

[2] Ghanshani S, Coleman M, Gustavsson P, Wu AH, Gargus JJ, Gutman GA, Dahl N, Mohrenweiser H, Chandy KG. Human calcium-activated potassium channel gene KCNN4 maps to chromosome 19q13.2 in the region deleted in diamond-blackfan anemia. Genomics. 1998. URL: https://www.semanticscholar.org/paper/7cae9cf00114e5428cd364ca986570df110ead07

[3] Simms LA, Doecke JD, Roberts R, Fowler E, Zhao ZZ, McGuckin MA, Huang N, Hayward NK, Webb PM, Whiteman DC, Cavanaugh JA, McCallum R, Florin TH, Barclay ML, Gearry RB, Merriman TR, Montgomery GW, Radford-Smith GL. KCNN4 Gene Variant Is Associated With Ileal Crohn's Disease in the Australian and New Zealand Population. American Journal of Gastroenterology. 2010. URL: https://www.semanticscholar.org/paper/52c63817ce32724ce0c9452f25b88fea7e5c5526

[4] Yamaguchi M, Nakayama T, Fu Z, Naganuma T, Sato N, Soma M, Doba N, Hinohara S, Morita A, Mizutani T. Relationship between haplotypes of KCNN4 gene and susceptibility to human vascular diseases in Japanese. Medical Science Monitor. 2009. URL: https://www.semanticscholar.org/paper/814ba07847c7e9f447042b9f27299d35e9a3c9e0

[5] Chu Z, Liu L, Wu H, Lai W. The effects of short interfering RNAs on KCNN4 gene expression and biological behaviors of LoVo cells. 2011. URL: https://www.semanticscholar.org/paper/7c5e8905547f53679da480b9b4d878a543aad2b2

[6] Zieleński J, Markiewicz D, Yuan X, Patel M, Sun L, Aznarez I, Tsui LC. Meconium ileus in cystic fibrosis neonates is associated with polymorphic markers in the calcium-activated potassium channel (KCNN4) gene. Journal of Pediatric Gastroenterology and Nutrition. 2004. URL: https://www.semanticscholar.org/paper/012b61ecd2084d52a1cf917cd2310210b267029d

[7] Simms LA, Doecke JD, Fowler E, Zhao ZZ, McGuckin MA, Huang N, Hayward NK, Webb PM, Whiteman DC, Cavanaugh JA, McCallum R, Merriman TR, Florin TH, Barclay ML, Gearry RB, Roberts R, Montgomery GW, Radford-Smith GL. KCNN4 Gene Variant Is Associated with Ileal Crohn's Disease. 2009. URL: https://www.semanticscholar.org/paper/6bba69645b5316e1696bbf1122c258bd633fefd9

[8] Kuriyama M, Hirose H, Kawaguchi Y, Michibata J, Maekawa M, Futaki S. KCNN4 as a Genomic Determinant of Cytosolic Delivery by the Attenuated Cationic Lytic Peptide L17E